SCHEMBL10166356

SCHEMBL10166356

O=C(c1ccc(Nc2ccc(-c3ccc4c(c3)CNCO4)n3ccnc23)cc1)N1CCC(N2CCCCC2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 9/20 0.42
L3MBTL1 Q9Y468 7/20 0.42
MKNK1 Q9BUB5 3/20 0.42
MKNK2 Q9HBH9 3/20 0.42
IKBKB O14920 6/20 0.41
CHUK O15111 6/20 0.41
IKBKG Q9Y6K9 6/20 0.41
MEN1 O00255 1/20 0.41
RECQL P46063 1/20 0.41
BLM P54132 1/20 0.41
KMT2A Q03164 1/20 0.41
PRKCZ Q05513 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MBTD1 Q05BQ5 7/20 0.40
TP53BP1 Q12888 2/20 0.40
L3MBTL4 Q8NA19 2/20 0.40
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
CHRM5 P08912 1/20 0.40
CHRM1 P11229 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10166412 0.94 L3MBTL3 (0.37) L3MBTL3L3MBTL1MKNK1MKNK2IKBKB
SCHEMBL10166430 0.92 ADRA1A (0.40) L3MBTL3L3MBTL1IKBKBCHUKIKBKG
SCHEMBL10166351 0.88 MAPKAPK5 (0.43) MKNK1MKNK2
SCHEMBL10166425 0.88 ALDH1A1 (0.41) L3MBTL1MEN1KMT2A
SCHEMBL10166405 0.86 IKBKB (0.38) MKNK1MKNK2IKBKBCHUKIKBKG
SCHEMBL10166437 0.85 CCND1 (0.37) PIK3CAMTOR
SCHEMBL10166161 0.85 CDK6 (0.37) PIK3CAMTORPIK3CG
SCHEMBL1685144 0.85 MAPKAPK5 (0.47) L3MBTL3L3MBTL1MKNK1MKNK2IKBKB
SCHEMBL10166841 0.84 VNN1 (0.39) IKBKBCHUKIKBKGPIK3CAMTOR
SCHEMBL10165790 0.83 MAPKAPK2 (0.35) PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES COL2A1, MMP1, COL1A1 L3MBTL3 4857/4885L3MBTL1 4815/4885MKNK1 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.